{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:49:31Z","timestamp":1792615771435,"version":"4.5.0"},"reference-count":151,"publisher":"Japanese Society of Veterinary Science","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Vet. Med. Sci.","The Journal of Veterinary Medical Science"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1292\/jvms.25-0040","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T22:06:56Z","timestamp":1744754816000},"page":"647-666","source":"Crossref","is-referenced-by-count":4,"title":["Sodium-glucose co-transporter 2 inhibitors: Prospects for canine myxomatous mitral valve disease and finding the \u201cright drug\u201d and the \u201cright dose\u201d for dogs"],"prefix":"10.1292","volume":"87","author":[{"given":"Mutsuki","family":"UMEZAWA","sequence":"first","affiliation":[{"name":"Laboratory of Small Animal Surgery, School of Veterinary Medicine, Azabu University, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"FUJII","sequence":"additional","affiliation":[{"name":"Laboratory of Small Animal Surgery, School of Veterinary Medicine, Azabu University, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"ORITO","sequence":"additional","affiliation":[{"name":"Laboratory of Physiology II, School of Veterinary Medicine, Azabu University, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"YOSHIMOTO","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacology, School of Veterinary Medicine, Azabu University, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"122","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Adamson PB, Suarez J, Ellis E, Kanaly T, Vanoli E.  2004. Ephedrine increases ventricular arrhythmias in conscious dogs after myocardial infarction. <i>J Am Coll Cardiol<\/i> 44: 1675\u20131678.","DOI":"10.1016\/j.jacc.2004.07.041"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Adin D, Atkins C, Londo\u00f1o L, Del Nero B.  2021. Correction of serum chloride concentration in dogs with congestive heart failure. <i>J Vet Intern Med<\/i> 35: 51\u201357.","DOI":"10.1111\/jvim.15998"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Adin D, Kurtz K, Atkins C, Papich MG, Vaden S.  2020. Role of electrolyte concentrations and renin-angiotensin-aldosterone activation in the staging of canine heart disease. <i>J Vet Intern Med<\/i> 34: 53\u201364.","DOI":"10.1111\/jvim.15662"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Al Jobori H, Daniele G, Adams J, Cersosimo E, Triplitt C, DeFronzo RA, Abdul-Ghani M.  2017. Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients. <i>Diabetes Obes Metab<\/i> 19: 809\u2013813.","DOI":"10.1111\/dom.12881"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M, Brunner-La Rocca HP, Choi DJ, Chopra V, Chuquiure-Valenzuela E, Giannetti N, Gomez-Mesa JE, Janssens S, Januzzi JL, Gonzalez-Juanatey JR, Merkely B, Nicholls SJ, Perrone SV, Pi\u00f1a IL, Ponikowski P, Senni M, Sim D, Spinar J, Squire I, Taddei S, Tsutsui H, Verma S, Vinereanu D, Zhang J, Carson P, Lam CSP, Marx N, Zeller C, Sattar N, Jamal W, Schnaidt S, Schnee JM, Brueckmann M, Pocock SJ, Zannad F, Packer M. EMPEROR-Preserved Trial Investigators 2021. Empagliflozin in heart failure with a preserved ejection fraction. <i>N Engl J Med<\/i> 385: 1451\u20131461.","DOI":"10.1056\/NEJMoa2107038"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Aubert G, Martin OJ, Horton JL, Lai L, Vega RB, Leone TC, Koves T, Gardell SJ, Kr\u00fcger M, Hoppel CL, Lewandowski ED, Crawford PA, Muoio DM, Kelly DP.  2016. The failing heart relies on ketone bodies as a fuel. <i>Circulation<\/i> 133: 698\u2013705.","DOI":"10.1161\/CIRCULATIONAHA.115.017355"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Avgerinos I, Karagiannis T, Matthews DR, Tsapas A, Bekiari E.  2023. Effects of sodium-glucose co-transporter-2 inhibitors by background cardiovascular medications: A systematic review and meta-analysis. <i>Diabetes Obes Metab<\/i> 25: 3020\u20133029.","DOI":"10.1111\/dom.15200"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Baartscheer A, Schumacher CA, W\u00fcst RCI, Fiolet JWT, Stienen GJM, Coronel R, Zuurbier CJ.  2017. Empagliflozin decreases myocardial cytoplasmic Na<sup>+<\/sup> through inhibition of the cardiac Na<sup>+<\/sup>\/H<sup>+<\/sup> exchanger in rats and rabbits. <i>Diabetologia<\/i> 60: 568\u2013573.","DOI":"10.1007\/s00125-016-4134-x"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Basit A, Radi Z, Vaidya VS, Karasu M, Prasad B.  2019. Kidney cortical transporter expression across species using quantitative proteomics. <i>Drug Metab Dispos<\/i> 47: 802\u2013808.","DOI":"10.1124\/dmd.119.086579"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Bedi KCJ Jr, Snyder NW, Brandimarto J, Aziz M, Mesaros C, Worth AJ, Wang LL, Javaheri A, Blair IA, Margulies KB, Rame JE.  2016. Evidence for intramyocardial disruption of lipid metabolism and increased myocardial ketone utilization in advanced human heart failure. <i>Circulation<\/i> 133: 706\u2013716.","DOI":"10.1161\/CIRCULATIONAHA.115.017545"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Bisignano P, Ghezzi C, Jo H, Polizzi NF, Althoff T, Kalyanaraman C, Friemann R, Jacobson MP, Wright EM, Grabe M.  2018. Inhibitor binding mode and allosteric regulation of Na<sup>+<\/sup>-glucose symporters. <i>Nat Commun<\/i> 9: 5245.","DOI":"10.1038\/s41467-018-07700-1"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Borgarelli M, Ferasin L, Lamb K, Bussadori C, Chiavegato D, D\u2019Agnolo G, Migliorini F, Poggi M, Santilli RA, Guillot E, Garelli-Paar C, Toschi Corneliani R, Farina F, Zani A, Dirven M, Smets P, Guglielmini C, Oliveira P, Di Marcello M, Porciello F, Crosara S, Ciaramella P, Piantedosi D, Smith S, Vannini S, Dall\u2019Aglio E, Savarino P, Quintavalla C, Patteson M, Silva J, Locatelli C, Baron Toaldo M.  2020. DELay of appearance of sYmptoms of canine degenerative mitral valve disease treated with spironolactone and benazepril: The DELAY study. <i>J Vet Cardiol<\/i> 27: 34\u201353.","DOI":"10.1016\/j.jvc.2019.12.002"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Boswood A, H\u00e4ggstr\u00f6m J, Gordon SG, Wess G, Stepien RL, Oyama MA, Keene BW, Bonagura J, MacDonald KA, Patteson M, Smith S, Fox PR, Sanderson K, Woolley R, Szatm\u00e1ri V, Menaut P, Church WM, O\u2019Sullivan ML, Jaudon JP, Kresken JG, Rush J, Barrett KA, Rosenthal SL, Saunders AB, Ljungvall I, Deinert M, Bomassi E, Estrada AH, Fernandez Del Palacio MJ, Moise NS, Abbott JA, Fujii Y, Spier A, Luethy MW, Santilli RA, Uechi M, Tidholm A, Watson P.  2016. Effect of pimobendan in dogs with preclinical myxomatous mitral valve disease and cardiomegaly: The EPIC study-A randomized clinical trial. <i>J Vet Intern Med<\/i> 30: 1765\u20131779.","DOI":"10.1111\/jvim.14586"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Boswood A, Gordon SG, H\u00e4ggstr\u00f6m J, Vanselow M, Wess G, Stepien RL, Oyama MA, Keene BW, Bonagura J, MacDonald KA, Patteson M, Smith S, Fox PR, Sanderson K, Woolley R, Szatm\u00e1ri V, Menaut P, Church WM, O\u2019Sullivan ML, Jaudon JP, Kresken JG, Rush J, Barrett KA, Rosenthal SL, Saunders AB, Ljungvall I, Deinert M, Bomassi E, Estrada AH, Fernandez Del Palacio MJ, Moise NS, Abbott JA, Fujii Y, Spier A, Luethy MW, Santilli RA, Uechi M, Tidholm A, Schummer C, Watson P.  2020. Temporal changes in clinical and radiographic variables in dogs with preclinical myxomatous mitral valve disease: the EPIC study. <i>J Vet Intern Med<\/i> 34: 1108\u20131118.","DOI":"10.1111\/jvim.15753"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Butler J, Fonarow GC, Zile MR, Lam CS, Roessig L, Schelbert EB, Shah SJ, Ahmed A, Bonow RO, Cleland JGF, Cody RJ, Chioncel O, Collins SP, Dunnmon P, Filippatos G, Lefkowitz MP, Marti CN, McMurray JJ, Misselwitz F, Nodari S, O\u2019Connor C, Pfeffer MA, Pieske B, Pitt B, Rosano G, Sabbah HN, Senni M, Solomon SD, Stockbridge N, Teerlink JR, Georgiopoulou VV, Gheorghiade M.  2014. Developing therapies for heart failure with preserved ejection fraction: current state and future directions. <i>JACC Heart Fail<\/i> 2: 97\u2013112.","DOI":"10.1016\/j.jchf.2013.10.006"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Byrne NJ, Matsumura N, Maayah ZH, Ferdaoussi M, Takahara S, Darwesh AM, Levasseur JL, Jahng JWS, Vos D, Parajuli N, El-Kadi AOS, Braam B, Young ME, Verma S, Light PE, Sweeney G, Seubert JM, Dyck JRB.  2020. Empagliflozin blunts worsening cardiac dysfunction associated with reduced NLRP3 (nucleotide-binding domain-like receptor protein 3) inflammasome activation in heart failure. <i>Circ Heart Fail<\/i> 13: e006277.","DOI":"10.1161\/CIRCHEARTFAILURE.119.006277"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Cai X, Yang W, Gao X, Chen Y, Zhou L, Zhang S, Han X, Ji L.  2018. The association between the dosage of SGLT2 inhibitor and weight reduction in type 2 diabetes patients: a meta-analysis. <i>Obesity (Silver Spring)<\/i> 26: 70\u201380.","DOI":"10.1002\/oby.22066"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Capozzi ME, Coch RW, Koech J, Astapova II, Wait JB, Encisco SE, Douros JD, El K, Finan B, Sloop KW, Herman MA, D\u2019Alessio DA, Campbell JE.  2020. The limited role of glucagon for ketogenesis during fasting or in response to SGLT2 inhibition. <i>Diabetes<\/i> 69: 882\u2013892.","DOI":"10.2337\/db19-1216"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Cappetta D, De Angelis A, Ciuffreda LP, Coppini R, Cozzolino A, Miccich\u00e8 A, Dell\u2019Aversana C, D\u2019Amario D, Cianflone E, Scavone C, Santini L, Palandri C, Naviglio S, Crea F, Rota M, Altucci L, Rossi F, Capuano A, Urbanek K, Berrino L.  2020. Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium. <i>Pharmacol Res<\/i> 157: 104781.","DOI":"10.1016\/j.phrs.2020.104781"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Carluccio E, Biagioli P, Reboldi G, Mengoni A, Lauciello R, Zuchi C, D\u2019Addario S, Bardelli G, Ambrosio G.  2023. Left ventricular remodeling response to SGLT2 inhibitors in heart failure: an updated meta-analysis of randomized controlled studies. <i>Cardiovasc Diabetol<\/i> 22: 235.","DOI":"10.1186\/s12933-023-01970-w"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Chae H, Augustin R, Gatineau E, Mayoux E, Bensellam M, Antoine N, Khattab F, Lai BK, Brusa D, Stierstorfer B, Klein H, Singh B, Ruiz L, Pieper M, Mark M, Herrera PL, Gribble FM, Reimann F, Wojtusciszyn A, Broca C, Rita N, Piemonti L, Gilon P.  2020. SGLT2 is not expressed in pancreatic \u03b1- and \u03b2-cells, and its inhibition does not directly affect glucagon and insulin secretion in rodents and humans. <i>Mol Metab<\/i> 42: 101071.","DOI":"10.1016\/j.molmet.2020.101071"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Chao EC, Henry RR.  2010. SGLT2 inhibition-a novel strategy for diabetes treatment. <i>Nat Rev Drug Discov<\/i> 9: 551\u2013559.","DOI":"10.1038\/nrd3180"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Chen J, Williams S, Ho S, Loraine H, Hagan D, Whaley JM, Feder JN.  2010. Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. <i>Diabetes Ther<\/i> 1: 57\u201392.","DOI":"10.1007\/s13300-010-0006-4"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Chen L, LaRocque LM, Efe O, Wang J, Sands JM, Klein JD.  2016. Effect of dapagliflozin treatment on fluid and electrolyte balance in diabetic rats. <i>Am J Med Sci<\/i> 352: 517\u2013523.","DOI":"10.1016\/j.amjms.2016.08.015"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Chen S, Wang Q, Bakker D, Hu X, Zhang L, van der Made I, Tebbens AM, Kov\u00e1csh\u00e1zi C, Giricz Z, Brenner GB, Ferdinandy P, Schaart G, Gemmink A, Hesselink MKC, Rivaud MR, Pieper MP, Hollmann MW, Weber NC, Balligand JL, Creemers EE, Coronel R, Zuurbier CJ.  2024. Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2. <i>Basic Res Cardiol<\/i> 119: 751\u2013772.","DOI":"10.1007\/s00395-024-01067-9"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Chertow GM, Correa-Rotter R, Vart P, Jongs N, McMurray JJV, Rossing P, Langkilde AM, Sj\u00f6str\u00f6m CD, Toto RD, Wheeler DC, Heerspink HJL. DAPA\u2010CKD Trial Committees and Investigators. 2023. Effects of dapagliflozin in chronic kidney disease, with and without other cardiovascular medications: DAPA-CKD trial. <i>J Am Heart Assoc<\/i> 12: e028739.","DOI":"10.1161\/JAHA.122.028739"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Chetboul V, Tissier R.  2012. Echocardiographic assessment of canine degenerative mitral valve disease. <i>J Vet Cardiol<\/i> 14: 127\u2013148.","DOI":"10.1016\/j.jvc.2011.11.005"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Choi MK, Song IS.  2012. Characterization of efflux transport of the PDE5 inhibitors, vardenafil and sildenafil. <i>J Pharm Pharmacol<\/i> 64: 1074\u20131083.","DOI":"10.1111\/j.2042-7158.2012.01498.x"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Chompoosan C, Buranakarl C, Chaiyabutr N, Chansaisakorn W.  2014. Decreased sympathetic tone after short-term treatment with enalapril in dogs with mild chronic mitral valve disease. <i>Res Vet Sci<\/i> 96: 347\u2013354.","DOI":"10.1016\/j.rvsc.2014.01.006"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Coffman M, Guillot E, Blondel T, Garelli-Paar C, Feng S, Heartsill S, Atkins CE.  2021. Clinical efficacy of a benazepril and spironolactone combination in dogs with congestive heart failure due to myxomatous mitral valve disease: The BEnazepril Spironolactone STudy (BESST). <i>J Vet Intern Med<\/i> 35: 1673\u20131687.","DOI":"10.1111\/jvim.16155"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Connelly KA, Zhang Y, Visram A, Advani A, Batchu SN, Desjardins JF, Thai K, Gilbert RE.  2019. Empagliflozin improves diastolic function in a nondiabetic rodent model of heart failure with preserved ejection fraction. <i>JACC Basic Transl Sci<\/i> 4: 27\u201337.","DOI":"10.1016\/j.jacbts.2018.11.010"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Convey V, Huh T, Achilles EJ, Massey LK, McKaba VF, Loughran KA, Kraus MS, Gelzer AR, Crooks AV, Oyama MA.  2024. Urine sodium concentration after intravenous furosemide in dogs with acute congestive heart failure and correlation with treatment efficacy. <i>J Vet Intern Med<\/i> 38: 71\u201380.","DOI":"10.1111\/jvim.16955"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Daniele G, Xiong J, Solis-Herrera C, Merovci A, Eldor R, Tripathy D, DeFronzo RA, Norton L, Abdul-Ghani M.  2016. Dapagliflozin enhances fat oxidation and ketone production in patients with type 2 diabetes. <i>Diabetes Care<\/i> 39: 2036\u20132041.","DOI":"10.2337\/dc15-2688"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. de Oliveira TL, Lincevicius GS, Shimoura CG, Sim\u00f5es-Sato AY, Garcia MLT, T Bergamaschi C, R Campos R.  2021. Effects of renal denervation on cardiovascular, metabolic and renal functions in streptozotocin-induced diabetic rats. <i>Life Sci<\/i> 278: 119534.","DOI":"10.1016\/j.lfs.2021.119534"},{"key":"35","unstructured":"35. Dhingra N, Verma S, Butler J, Nwajei E. SGLT2 inhibition in subjects with valvular heart disease: a pooled analysis of the EMPEROR program. https:\/\/www.aats.org\/resources\/abstract.pdf?abstract=2428566 [accessed on January 29, 2025]."},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. DiBona GF, Kopp UC.  1997. Neural control of renal function. <i>Physiol Rev<\/i> 77: 75\u2013197.","DOI":"10.1152\/physrev.1997.77.1.75"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Ferrannini E, Baldi S, Frascerra S, Astiarraga B, Heise T, Bizzotto R, Mari A, Pieber TR, Muscelli E.  2016. Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. <i>Diabetes<\/i> 65: 1190\u20131195.","DOI":"10.2337\/db15-1356"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Giorgi ME, Mochel JP, Yuan L, Adin DB, Ward JL.  2022. Retrospective evaluation of risk factors for development of kidney injury after parenteral furosemide treatment of left-sided congestive heart failure in dogs. <i>J Vet Intern Med<\/i> 36: 2042\u20132052.","DOI":"10.1111\/jvim.16571"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Gopalasingam N, Berg-Hansen K, Christensen KH, Ladefoged BT, Poulsen SH, Andersen MJ, Borlaug BA, Nielsen R, M\u00f8ller N, Wiggers H.  2024. Randomized crossover trial of 2-week ketone ester treatment in patients with type 2 diabetes and heart failure with preserved ejection fraction. <i>Circulation<\/i> 150: 1570\u20131583.","DOI":"10.1161\/CIRCULATIONAHA.124.069732"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Gorboulev V, Sch\u00fcrmann A, Vallon V, Kipp H, Jaschke A, Klessen D, Friedrich A, Scherneck S, Rieg T, Cunard R, Veyhl-Wichmann M, Srinivasan A, Balen D, Breljak D, Rexhepaj R, Parker HE, Gribble FM, Reimann F, Lang F, Wiese S, Sabolic I, Sendtner M, Koepsell H.  2012. Na<sup>+<\/sup>-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. <i>Diabetes<\/i> 61: 187\u2013196.","DOI":"10.2337\/db11-1029"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Goutal CM, Keir I, Kenney S, Rush JE, Freeman LM.  2010. Evaluation of acute congestive heart failure in dogs and cats: 145 cases (2007\u20132008). <i>J Vet Emerg Crit Care (San Antonio)<\/i> 20: 330\u2013337.","DOI":"10.1111\/j.1476-4431.2010.00524.x"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Graham MJ, Lake BG.  2008. Induction of drug metabolism: species differences and toxicological relevance. <i>Toxicology<\/i> 254: 184\u2013191.","DOI":"10.1016\/j.tox.2008.09.002"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Gu N, Park SI, Chung H, Jin X, Lee S, Kim TE.  2020. Possibility of pharmacokinetic drug interaction between a DPP-4 inhibitor and a SGLT2 inhibitor. <i>Transl Clin Pharmacol<\/i> 28: 17\u201333.","DOI":"10.12793\/tcp.2020.28.e4"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. H\u00e4ggstr\u00f6m J, Hamlin RL, Hansson K, Kvart C.  1996. Heart rate variability in relation to severity of mitral regurgitation in Cavalier King Charles spaniels. <i>J Small Anim Pract<\/i> 37: 69\u201375.","DOI":"10.1111\/j.1748-5827.1996.tb01941.x"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Hahn VS, Petucci C, Kim MS, Bedi KCJ Jr, Wang H, Mishra S, Koleini N, Yoo EJ, Margulies KB, Arany Z, Kelly DP, Kass DA, Sharma K.  2023. Myocardial metabolomics of human heart failure with preserved ejection fraction. <i>Circulation<\/i> 147: 1147\u20131161.","DOI":"10.1161\/CIRCULATIONAHA.122.061846"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Hallow KM, Helmlinger G, Greasley PJ, McMurray JJV, Boulton DW.  2018. Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. <i>Diabetes Obes Metab<\/i> 20: 479\u2013487.","DOI":"10.1111\/dom.13126"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Hanberg JS, Rao V, Ter Maaten JM, Laur O, Brisco MA, Perry Wilson F, Grodin JL, Assefa M, Samuel Broughton J, Planavsky NJ, Ahmad T, Bellumkonda L, Tang WHW, Parikh CR, Testani JM.  2016. Hypochloremia and diuretic resistance in heart failure: Mechanistic insights. <i>Circ Heart Fail<\/i> 9: e003180.","DOI":"10.1161\/CIRCHEARTFAILURE.116.003180"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. He Y, Schofield J, Mahling P, Mendonza AE, Hinder M.  2020. Investigation and management of stool frequency and consistency associated with SGLT1 inhibition by reducing dietary carbohydrate: A randomized trial. <i>Clin Pharmacol Ther<\/i> 108: 995\u20131002.","DOI":"10.1002\/cpt.1840"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Heerspink HJL, Cherney DZI.  2021. Clinical implications of an acute dip in eGFR after SGLT2 inhibitor initiation. <i>Clin J Am Soc Nephrol<\/i> 16: 1278\u20131280.","DOI":"10.2215\/CJN.02480221"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sj\u00f6str\u00f6m CD, Toto RD, Langkilde AM, Wheeler DC. DAPA-CKD Trial Committees and Investigators. 2020. Dapagliflozin in patients with chronic kidney disease. <i>N Engl J Med<\/i> 383: 1436\u20131446.","DOI":"10.1056\/NEJMoa2024816"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Herat LY, Magno AL, Rudnicka C, Hricova J, Carnagarin R, Ward NC, Arcambal A, Kiuchi MG, Head GA, Schlaich MP, Matthews VB.  2020. SGLT2 inhibitor-induced sympathoinhibition: A novel mechanism for cardiorenal protection. <i>JACC Basic Transl Sci<\/i> 5: 169\u2013179.","DOI":"10.1016\/j.jacbts.2019.11.007"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Higashi H, Watanabe N, Tamura R, Taguchi M.  2017. <i>In vitro<\/i> P-glycoprotein-mediated transport of tadalafil: A comparison with sildenafil. <i>Biol Pharm Bull<\/i> 40: 1314\u20131319.","DOI":"10.1248\/bpb.b17-00278"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Higashikawa T, Ito T, Mizuno T, Ishigami K, Kohori M, Mae K, Usuda D, Takagi S, Sangen R, Saito A, Iguchi M, Kasamaki Y, Fukuda A, Kanda T, Okuro M.  2020. Effects of tofogliflozin on cardiac function in elderly patients with diabetes mellitus. <i>J Clin Med Res<\/i> 12: 165\u2013171.","DOI":"10.14740\/jocmr4098"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Higashikuni Y, Tanaka K, Kato M, Nureki O, Hirata Y, Nagai R, Komuro I, Sata M.  2013. Toll-like receptor-2 mediates adaptive cardiac hypertrophy in response to pressure overload through interleukin-1\u03b2 upregulation via nuclear factor \u03baB activation. <i>J Am Heart Assoc<\/i> 2: e000267.","DOI":"10.1161\/JAHA.113.000267"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Higashikuni Y, Liu W, Numata G, Tanaka K, Fukuda D, Tanaka Y, Hirata Y, Imamura T, Takimoto E, Komuro I, Sata M.  2023. NLRP3 inflammasome activation through heart-brain interaction initiates cardiac inflammation and hypertrophy during pressure overload. <i>Circulation<\/i> 147: 338\u2013355.","DOI":"10.1161\/CIRCULATIONAHA.122.060860"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Ho KL, Karwi QG, Wagg C, Zhang L, Vo K, Altamimi T, Uddin GM, Ussher JR, Lopaschuk GD.  2021. Ketones can become the major fuel source for the heart but do not increase cardiac efficiency. <i>Cardiovasc Res<\/i> 117: 1178\u20131187.","DOI":"10.1093\/cvr\/cvaa143"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. Honsho S, Nishikawa S, Amano K, Zen K, Adachi Y, Kishita E, Matsui A, Katsume A, Yamaguchi S, Nishikawa K, Isoda K, Riches DWH, Matoba S, Okigaki M, Matsubara H.  2009. Pressure-mediated hypertrophy and mechanical stretch induces IL-1 release and subsequent IGF-1 generation to maintain compensative hypertrophy by affecting Akt and JNK pathways. <i>Circ Res<\/i> 105: 1149\u20131158.","DOI":"10.1161\/CIRCRESAHA.109.208199"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. Hori M, Sasayama S, Kitabatake A, Toyo-oka T, Handa S, Yokoyama M, Matsuzaki M, Takeshita A, Origasa H, Matsui K, Hosoda S. MUCHA Investigators. 2004. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. <i>Am Heart J<\/i> 147: 324\u2013330.","DOI":"10.1016\/j.ahj.2003.07.023"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59. Huang ZS, Fan R, Xie PH, Zhong JL, Zhang SZ, Zhuang XD, Liao XX.  2023. Dapagliflozin effect on functional mitral regurgitation and myocardial remodeling (DEFORM trial). <i>Eur Heart J<\/i> 44: ehad655.1751.","DOI":"10.1093\/eurheartj\/ehad655.1751"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60. Iijima H, Kifuji T, Maruyama N, Inagaki N.  2015. Pharmacokinetics, pharmacodynamics, and safety of canagliflozin in Japanese patients with type 2 diabetes mellitus. <i>Adv Ther<\/i> 32: 768\u2013782.","DOI":"10.1007\/s12325-015-0234-0"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61. Iskander C, Cherney DZ, Clemens KK, Dixon SN, Harel Z, Jeyakumar N, McArthur E, Muanda FT, Parikh CR, Paterson JM, Tangri N, Udell JA, Wald R, Garg AX.  2020. Use of sodium-glucose cotransporter-2 inhibitors and risk of acute kidney injury in older adults with diabetes: a population-based cohort study. <i>CMAJ<\/i> 192: E351\u2013E360.","DOI":"10.1503\/cmaj.191283"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62. Jiang K, Xu Y, Wang D, Chen F, Tu Z, Qian J, Xu S, Xu Y, Hwa J, Li J, Shang H, Xiang Y.  2022. Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis. <i>Protein Cell<\/i> 13: 336\u2013359.","DOI":"10.1007\/s13238-020-00809-4"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63. Kalla M, Herring N, Paterson DJ.  2016. Cardiac sympatho-vagal balance and ventricular arrhythmia. <i>Auton Neurosci<\/i> 199: 29\u201337.","DOI":"10.1016\/j.autneu.2016.08.016"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64. Kanada S, Koiwai K, Taniguchi A, Sarashina A, Seman L, Woerle HJ.  2013. Pharmacokinetics, pharmacodynamics, safety and tolerability of 4 weeks\u2019 treatment with empagliflozin in Japanese patients with type 2 diabetes mellitus. <i>J Diabetes Investig<\/i> 4: 613\u2013617.","DOI":"10.1111\/jdi.12110"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65. Kang DH, Park SJ, Shin SH, Hwang IC, Yoon YE, Kim HK, Kim M, Kim MS, Yun SC, Song JM, Kang SM.  2024. Ertugliflozin for functional mitral regurgitation associated with heart failure: EFFORT trial. <i>Circulation<\/i> 149: 1865\u20131874.","DOI":"10.1161\/CIRCULATIONAHA.124.069144"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66. Kasichayanula S, Chang M, Hasegawa M, Liu X, Yamahira N, LaCreta FP, Imai Y, Boulton DW.  2011. Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus. <i>Diabetes Obes Metab<\/i> 13: 357\u2013365.","DOI":"10.1111\/j.1463-1326.2011.01359.x"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67. Kataoka H, Yoshida Y.  2020. Enhancement of the serum chloride concentration by administration of sodium-glucose cotransporter-2 inhibitor and its mechanisms and clinical significance in type 2 diabetic patients: a pilot study. <i>Diabetol Metab Syndr<\/i> 12: 5.","DOI":"10.1186\/s13098-020-0515-x"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68. Katsurada K, Patel KP.  2024. The role of afferent renal nerves in regulating sympathetic outflow via central nervous system mechanisms. <i>Hypertens Res<\/i> 47: 1978\u20131980.","DOI":"10.1038\/s41440-024-01677-9"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69. Katsurada K, Nandi SS, Sharma NM, Patel KP.  2021. Enhanced expression and function of renal SGLT2 (sodium-glucose cotransporter 2) in heart failure: Role of renal nerves. <i>Circ Heart Fail<\/i> 14: e008365.","DOI":"10.1161\/CIRCHEARTFAILURE.121.008365"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70. Kaur J, Young BE, Fadel PJ.  2017. Sympathetic overactivity in chronic kidney disease: Consequences and mechanisms. <i>Int J Mol Sci<\/i> 18: 1682.","DOI":"10.3390\/ijms18081682"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71. Keene BW, Atkins CE, Bonagura JD, Fox PR, H\u00e4ggstr\u00f6m J, Fuentes VL, Oyama MA, Rush JE, Stepien R, Uechi M.  2019. ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs. <i>J Vet Intern Med<\/i> 33: 1127\u20131140.","DOI":"10.1111\/jvim.15488"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72. Kim SR, Lee SG, Kim SH, Kim JH, Choi E, Cho W, Rim JH, Hwang I, Lee CJ, Lee M, Oh CM, Jeon JY, Gee HY, Kim JH, Lee BW, Kang ES, Cha BS, Lee MS, Yu JW, Cho JW, Kim JS, Lee YH.  2020. SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. <i>Nat Commun<\/i> 11: 2127.","DOI":"10.1038\/s41467-020-15983-6"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73. Kintscher U, Foryst-Ludwig A, Haemmerle G, Zechner R.  2020. The role of adipose triglyceride lipase and cytosolic lipolysis in cardiac function and heart failure. <i>Cell Rep Med<\/i> 1: 100001.","DOI":"10.1016\/j.xcrm.2020.100001"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74. Knapp DW, Richardson RC, DeNicola DB, Long GG, Blevins WE.  1987. Cisplatin toxicity in cats. <i>J Vet Intern Med<\/i> 1: 29\u201335.","DOI":"10.1111\/j.1939-1676.1987.tb01983.x"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75. Kolman BS, Verrier RL, Lown B.  1975. The effect of vagus nerve stimulation upon vulnerability of the canine ventricle: role of sympathetic-parasympathetic interactions. <i>Circulation<\/i> 52: 578\u2013585.","DOI":"10.1161\/01.CIR.52.4.578"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76. Larouche-Lebel \u00c9, Loughran KA, Oyama MA, Solter PF, Laughlin DS, S\u00e1nchez MD, Assenmacher CA, Fox PR, Fries RC.  2019. Plasma and tissue angiotensin-converting enzyme 2 activity and plasma equilibrium concentrations of angiotensin peptides in dogs with heart disease. <i>J Vet Intern Med<\/i> 33: 1571\u20131584.","DOI":"10.1111\/jvim.15548"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77. Li Q.  2022. Metabolic reprogramming, gut dysbiosis, and nutrition intervention in canine heart disease. <i>Front Vet Sci<\/i> 9: 791754.","DOI":"10.3389\/fvets.2022.791754"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78. Li Q, Larouche-Lebel \u00c9, Loughran KA, Huh TP, Suchodolski JS, Oyama MA.  2021. Metabolomics analysis reveals deranged energy metabolism and amino acid metabolic reprogramming in dogs with myxomatous mitral valve disease. <i>J Am Heart Assoc<\/i> 10: e018923.","DOI":"10.1161\/JAHA.120.018923"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79. Lommi J, Kupari M, Yki-J\u00e4rvinen H.  1998. Free fatty acid kinetics and oxidation in congestive heart failure. <i>Am J Cardiol<\/i> 81: 45\u201350.","DOI":"10.1016\/S0002-9149(97)00804-7"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80. Lopaschuk GD, Verma S.  2020. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: A state-of-the-art review. <i>JACC Basic Transl Sci<\/i> 5: 632\u2013644.","DOI":"10.1016\/j.jacbts.2020.02.004"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81. Lovern CS, Swecker WS, Lee JC, Moon ML.  2001. Additive effects of a sodium chloride restricted diet and furosemide administration in healthy dogs. <i>Am J Vet Res<\/i> 62: 1793\u20131796.","DOI":"10.2460\/ajvr.2001.62.1793"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82. Lu J, Rohani S.  2009. Polymorphism and crystallization of active pharmaceutical ingredients (APIs). <i>Curr Med Chem<\/i> 16: 884\u2013905.","DOI":"10.2174\/092986709787549299"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83. Lu Q, Liu J, Li X, Sun X, Zhang J, Ren D, Tong N, Li J.  2020. Empagliflozin attenuates ischemia and reperfusion injury through LKB1\/AMPK signaling pathway. <i>Mol Cell Endocrinol<\/i> 501: 110642.","DOI":"10.1016\/j.mce.2019.110642"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84. Luna SPL, Bas\u00edlio AC, Steagall PVM, Machado LP, Moutinho FQ, Takahira RK, Brand\u00e3o CVS.  2007. Evaluation of adverse effects of long-term oral administration of carprofen, etodolac, flunixin meglumine, ketoprofen, and meloxicam in dogs. <i>Am J Vet Res<\/i> 68: 258\u2013264.","DOI":"10.2460\/ajvr.68.3.258"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85. Lund LH, Donal E, Oger E, Hage C, Persson H, Haugen-L\u00f6fman I, Ennezat PV, Sportouch-Dukhan C, Drouet E, Daubert JC, Linde C. KaRen Investigators. 2014. Association between cardiovascular vs. non-cardiovascular co-morbidities and outcomes in heart failure with preserved ejection fraction. <i>Eur J Heart Fail<\/i> 16: 992\u20131001.","DOI":"10.1002\/ejhf.137"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86. Ma HX, Wu K, Dong FH, Cai BK, Wu D, Lu HY.  2024. Effects of Empagliflozin and Dapagliflozin in alleviating cardiac fibrosis through SIRT6-mediated oxidative stress reduction. <i>Sci Rep<\/i> 14: 30764.","DOI":"10.1038\/s41598-024-80829-w"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87. Marfella R, Scisciola L, D\u2019Onofrio N, Maiello C, Trotta MC, Sardu C, Panarese I, Ferraraccio F, Capuano A, Barbieri M, Balestrieri ML, Napoli C, Paolisso G.  2022. Sodium-glucose cotransporter-2 (SGLT2) expression in diabetic and non-diabetic failing human cardiomyocytes. <i>Pharmacol Res<\/i> 184: 106448.","DOI":"10.1016\/j.phrs.2022.106448"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88. Martignoni M, Groothuis GMM, de Kanter R.  2006. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. <i>Expert Opin Drug Metab Toxicol<\/i> 2: 875\u2013894.","DOI":"10.1517\/17425255.2.6.875"},{"key":"89","doi-asserted-by":"crossref","unstructured":"89. Martinelli E, Locatelli C, Bassis S, Crosara S, Paltrinieri S, Scarpa P, Spalla I, Zanaboni AM, Quintavalla C, Brambilla P.  2016. Preliminary investigation of cardiovascular-renal disorders in dogs with chronic mitral valve disease. <i>J Vet Intern Med<\/i> 30: 1612\u20131618.","DOI":"10.1111\/jvim.14524"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90. Masuda T, Nagata D.  2023. Fluid homeostasis induced by sodium-glucose cotransporter 2 inhibitors: novel insight for better cardio-renal outcomes in chronic kidney disease. <i>Hypertens Res<\/i> 46: 1195\u20131201.","DOI":"10.1038\/s41440-023-01220-2"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91. Masuda T, Ohara K, Vallon V, Nagata D.  2022. SGLT2 inhibitor and loop diuretic induce different vasopressin and fluid homeostatic responses in nondiabetic rats. <i>Am J Physiol Renal Physiol<\/i> 323: F361\u2013F369.","DOI":"10.1152\/ajprenal.00070.2022"},{"key":"92","doi-asserted-by":"crossref","unstructured":"92. Matthews VB, Elliot RH, Rudnicka C, Hricova J, Herat L, Schlaich MP.  2017. Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2. <i>J Hypertens<\/i> 35: 2059\u20132068.","DOI":"10.1097\/HJH.0000000000001434"},{"key":"93","doi-asserted-by":"crossref","unstructured":"93. Mattin MJ, Boswood A, Church DB, Brodbelt DC.  2019. Prognostic factors in dogs with presumed degenerative mitral valve disease attending primary-care veterinary practices in the United Kingdom. <i>J Vet Intern Med<\/i> 33: 432\u2013444.","DOI":"10.1111\/jvim.15251"},{"key":"94","doi-asserted-by":"crossref","unstructured":"94. Mattin MJ, Brodbelt DC, Church DB, Boswood A.  2019. Factors associated with disease progression in dogs with presumed preclinical degenerative mitral valve disease attending primary care veterinary practices in the United Kingdom. <i>J Vet Intern Med<\/i> 33: 445\u2013454.","DOI":"10.1111\/jvim.15390"},{"key":"95","unstructured":"95. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, Burri H, Butler J, \u010celutkien\u0117 J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A. ESC Scientific Document Group. 2021. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>Eur Heart J<\/i> 42: 3599\u20133726."},{"key":"96","doi-asserted-by":"crossref","unstructured":"96. McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, B\u011blohl\u00e1vek J, B\u00f6hm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Duk\u00e1t A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O\u2019Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sj\u00f6strand M, Langkilde AM. DAPA-HF Trial Committees and Investigators. 2019. Dapagliflozin in patients with heart failure and reduced ejection fraction. <i>N Engl J Med<\/i> 381: 1995\u20132008.","DOI":"10.1056\/NEJMoa1911303"},{"key":"97","doi-asserted-by":"crossref","unstructured":"97. Mullard A.  2024. 2023 FDA approvals. <i>Nat Rev Drug Discov<\/i> 23: 88\u201395.","DOI":"10.1038\/d41573-024-00001-x"},{"key":"98","doi-asserted-by":"crossref","unstructured":"98. Nasi-Er BG, Lou X, Zhang Y, Sun H, Zhou X, Li Y, Zhou Q, Zhang J, Tang B, Lu Y.  2019. Renal sympathetic denervation improves outcomes in a canine myocardial infarction model. <i>Med Sci Monit<\/i> 25: 3887\u20133893.","DOI":"10.12659\/MSM.914384"},{"key":"99","doi-asserted-by":"crossref","unstructured":"99. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR. CANVAS Program Collaborative Group. 2017. Canagliflozin and cardiovascular and renal events in type 2 diabetes. <i>N Engl J Med<\/i> 377: 644\u2013657.","DOI":"10.1056\/NEJMoa1611925"},{"key":"100","doi-asserted-by":"crossref","unstructured":"100. Neuen BL, Young T, Heerspink HJL, Neal B, Perkovic V, Billot L, Mahaffey KW, Charytan DM, Wheeler DC, Arnott C, Bompoint S, Levin A, Jardine MJ.  2019. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. <i>Lancet Diabetes Endocrinol<\/i> 7: 845\u2013854.","DOI":"10.1016\/S2213-8587(19)30256-6"},{"key":"101","doi-asserted-by":"crossref","unstructured":"101. Novo G, Guarino T, Di Lisi D, Biagioli P, Carluccio E.  2023. Effects of SGLT2 inhibitors on cardiac structure and function. <i>Heart Fail Rev<\/i> 28: 697\u2013707.","DOI":"10.1007\/s10741-022-10256-4"},{"key":"102","doi-asserted-by":"crossref","unstructured":"102. Obermeier M, Yao M, Khanna A, Koplowitz B, Zhu M, Li W, Komoroski B, Kasichayanula S, Discenza L, Washburn W, Meng W, Ellsworth BA, Whaley JM, Humphreys WG.  2010. <i>In vitro<\/i> characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. <i>Drug Metab Dispos<\/i> 38: 405\u2013414.","DOI":"10.1124\/dmd.109.029165"},{"key":"103","doi-asserted-by":"crossref","unstructured":"103. Ohara K, Masuda T, Morinari M, Okada M, Miki A, Nakagawa S, Murakami T, Oka K, Asakura M, Miyazawa Y, Maeshima A, Akimoto T, Saito O, Nagata D.  2020. The extracellular volume status predicts body fluid response to SGLT2 inhibitor dapagliflozin in diabetic kidney disease. <i>Diabetol Metab Syndr<\/i> 12: 37.","DOI":"10.1186\/s13098-020-00545-z"},{"key":"104","doi-asserted-by":"crossref","unstructured":"104. Oliveira MS, Muzzi RAL, Ara\u00fajo RB, Muzzi LAL, Ferreira DF, Nogueira R, Silva EF.  2012. Heart rate variability parameters of myxomatous mitral valve disease in dogs with and without heart failure obtained using 24-hour Holter electrocardiography. <i>Vet Rec<\/i> 170: 622.","DOI":"10.1136\/vr.100202"},{"key":"105","doi-asserted-by":"crossref","unstructured":"105. Oshida K, Shimamura M, Seya K, Ando A, Miyamoto Y.  2017. Identification of transporters involved in beraprost sodium transport <i>in vitro<\/i>. <i>Eur J Drug Metab Pharmacokinet<\/i> 42: 117\u2013128.","DOI":"10.1007\/s13318-016-0327-4"},{"key":"106","doi-asserted-by":"crossref","unstructured":"106. Oyama MA, Adin D.  2023. Toward quantification of loop diuretic responsiveness for congestive heart failure. <i>J Vet Intern Med<\/i> 37: 12\u201321.","DOI":"10.1111\/jvim.16590"},{"key":"107","doi-asserted-by":"crossref","unstructured":"107. Oyama MA, Elliott C, Loughran KA, Kossar AP, Castillero E, Levy RJ, Ferrari G.  2020. Comparative pathology of human and canine myxomatous mitral valve degeneration: 5HT and TGF-\u03b2 mechanisms. <i>Cardiovasc Pathol<\/i> 46: 107196.","DOI":"10.1016\/j.carpath.2019.107196"},{"key":"108","doi-asserted-by":"crossref","unstructured":"108. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. U.S. Carvedilol Heart Failure Study Group. 1996. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. <i>N Engl J Med<\/i> 334: 1349\u20131355.","DOI":"10.1056\/NEJM199605233342101"},{"key":"109","doi-asserted-by":"crossref","unstructured":"109. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, B\u00f6hm M, Choi DJ, Chopra V, Chuquiure E, Giannetti N, Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, Brunner-La Rocca HP, Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M, Seronde MF, Spinar J, Squire I, Taddei S, Wanner C, Zannad F. EMPEROR-Reduced Trial Investigators 2020. Cardiovascular and renal outcomes with empagliflozin in heart failure. <i>N Engl J Med<\/i> 383: 1413\u20131424.","DOI":"10.1056\/NEJMoa2022190"},{"key":"110","doi-asserted-by":"crossref","unstructured":"110. Perry RJ, Rabin-Court A, Song JD, Cardone RL, Wang Y, Kibbey RG, Shulman GI.  2019. Dehydration and insulinopenia are necessary and sufficient for euglycemic ketoacidosis in SGLT2 inhibitor-treated rats. <i>Nat Commun<\/i> 10: 548.","DOI":"10.1038\/s41467-019-08466-w"},{"key":"111","unstructured":"111. Pharmaceuticals and Medical Devices Agency.https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuSearch\/ [accessed on January 29, 2025]."},{"key":"112","doi-asserted-by":"crossref","unstructured":"112. Philippaert K, Kalyaanamoorthy S, Fatehi M, Long W, Soni S, Byrne NJ, Barr A, Singh J, Wong J, Palechuk T, Schneider C, Darwesh AM, Maayah ZH, Seubert JM, Barakat K, Dyck JRB, Light PE.  2021. Cardiac late sodium channel current is a molecular target for the sodium\/glucose cotransporter 2 inhibitor empagliflozin. <i>Circulation<\/i> 143: 2188\u20132204.","DOI":"10.1161\/CIRCULATIONAHA.121.053350"},{"key":"113","doi-asserted-by":"crossref","unstructured":"113. Polak J, Kotrc M, Wedellova Z, Jabor A, Malek I, Kautzner J, Kazdova L, Melenovsky V.  2011. Lipolytic effects of B-type natriuretic peptide 1-32 in adipose tissue of heart failure patients compared with healthy controls. <i>J Am Coll Cardiol<\/i> 58: 1119\u20131125.","DOI":"10.1016\/j.jacc.2011.05.042"},{"key":"114","doi-asserted-by":"crossref","unstructured":"114. Polidori D, Iijima H, Goda M, Maruyama N, Inagaki N, Crawford PA.  2018. Intra- and inter-subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co-transporter 2 inhibitor canagliflozin. <i>Diabetes Obes Metab<\/i> 20: 1321\u20131326.","DOI":"10.1111\/dom.13224"},{"key":"115","doi-asserted-by":"crossref","unstructured":"115. Potter BM, Ames MK, Hess A, Poglitsch M.  2019. Comparison between the effects of torsemide and furosemide on the renin-angiotensin-aldosterone system of normal dogs. <i>J Vet Cardiol<\/i> 26: 51\u201362.","DOI":"10.1016\/j.jvc.2019.11.003"},{"key":"116","doi-asserted-by":"crossref","unstructured":"116. Rasmussen CE, Falk T, Zois NE, Moesgaard SG, H\u00e4ggstr\u00f6m J, Pedersen HD, Ablad B, Nilsen HY, Olsen LH.  2012. Heart rate, heart rate variability, and arrhythmias in dogs with myxomatous mitral valve disease. <i>J Vet Intern Med<\/i> 26: 76\u201384.","DOI":"10.1111\/j.1939-1676.2011.00842.x"},{"key":"117","doi-asserted-by":"crossref","unstructured":"117. Sabolic I, Vrhovac I, Eror DB, Gerasimova M, Rose M, Breljak D, Ljubojevic M, Brzica H, Sebastiani A, Thal SC, Sauvant C, Kipp H, Vallon V, Koepsell H.  2012. Expression of Na<sup>+<\/sup>-D-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences. <i>Am J Physiol Cell Physiol<\/i> 302: C1174\u2013C1188.","DOI":"10.1152\/ajpcell.00450.2011"},{"key":"118","doi-asserted-by":"crossref","unstructured":"118. Sack MN, Rader TA, Park S, Bastin J, McCune SA, Kelly DP.  1996. Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. <i>Circulation<\/i> 94: 2837\u20132842.","DOI":"10.1161\/01.CIR.94.11.2837"},{"key":"119","doi-asserted-by":"crossref","unstructured":"119. Sano M.  2018. A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity. <i>J Cardiol<\/i> 71: 471\u2013476.","DOI":"10.1016\/j.jjcc.2017.12.004"},{"key":"120","doi-asserted-by":"crossref","unstructured":"120. Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, Ishikawa K, Watanabe S, Picatoste B, Flores E, Garcia-Ropero A, Sanz J, Hajjar RJ, Fuster V, Badimon JJ.  2019. Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics. <i>J Am Coll Cardiol<\/i> 73: 1931\u20131944.","DOI":"10.1016\/j.jacc.2019.01.056"},{"key":"121","doi-asserted-by":"crossref","unstructured":"121. Sarashina A, Koiwai K, Seman LJ, Yamamura N, Taniguchi A, Negishi T, Sesoko S, Woerle HJ, Dugi KA.  2013. Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects. <i>Drug Metab Pharmacokinet<\/i> 28: 213\u2013219.","DOI":"10.2133\/dmpk.DMPK-12-RG-082"},{"key":"122","doi-asserted-by":"crossref","unstructured":"122. Saucedo-Orozco H, Voorrips SN, Yurista SR, de Boer RA, Westenbrink BD.  2022. SGLT2 inhibitors and ketone metabolism in heart failure. <i>J Lipid Atheroscler<\/i> 11: 1\u201319.","DOI":"10.12997\/jla.2022.11.1.1"},{"key":"123","doi-asserted-by":"crossref","unstructured":"123. Seki M, Powers JC, Maruyama S, Zuriaga MA, Wu CL, Kurishima C, Kim L, Johnson J, Poidomani A, Wang T, Mu\u00f1oz E, Rajan S, Park JY, Walsh K, Recchia FA.  2018. Acute and chronic increases of circulating FSTL1 normalize energy substrate metabolism in pacing-induced heart failure. <i>Circ Heart Fail<\/i> 11: e004486.","DOI":"10.1161\/CIRCHEARTFAILURE.117.004486"},{"key":"124","doi-asserted-by":"crossref","unstructured":"124. Sha S, Devineni D, Ghosh A, Polidori D, Chien S, Wexler D, Shalayda K, Demarest K, Rothenberg P.  2011. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. <i>Diabetes Obes Metab<\/i> 13: 669\u2013672.","DOI":"10.1111\/j.1463-1326.2011.01406.x"},{"key":"125","doi-asserted-by":"crossref","unstructured":"125. Shah N, Madanieh R, Alkan M, Dogar MU, Kosmas CE, Vittorio TJ.  2017. A perspective on diuretic resistance in chronic congestive heart failure. <i>Ther Adv Cardiovasc Dis<\/i> 11: 271\u2013278.","DOI":"10.1177\/1753944717718717"},{"key":"126","doi-asserted-by":"crossref","unstructured":"126. Shah SJ, Kitzman DW, Borlaug BA, van Heerebeek L, Zile MR, Kass DA, Paulus WJ.  2016. Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap. <i>Circulation<\/i> 134: 73\u201390.","DOI":"10.1161\/CIRCULATIONAHA.116.021884"},{"key":"127","doi-asserted-by":"crossref","unstructured":"127. Sokolov V, Yakovleva T, Chu L, Tang W, Greasley PJ, Johansson S, Peskov K, Helmlinger G, Boulton DW, Penland RC.  2020. Differentiating the sodium-glucose cotransporter 1 inhibition capacity of canagliflozin vs. dapagliflozin and empagliflozin using quantitative systems pharmacology modeling. <i>CPT Pharmacometrics Syst Pharmacol<\/i> 9: 222\u2013229.","DOI":"10.1002\/psp4.12498"},{"key":"128","doi-asserted-by":"crossref","unstructured":"128. Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, Jhund PS, Belohlavek J, Chiang CE, Borleffs CJW, Comin-Colet J, Dobreanu D, Drozdz J, Fang JC, Alcocer-Gamba MA, Al Habeeb W, Han Y, Cabrera Honorio JW, Janssens SP, Katova T, Kitakaze M, Merkely B, O\u2019Meara E, Saraiva JFK, Tereshchenko SN, Thierer J, Vaduganathan M, Vardeny O, Verma S, Pham VN, Wilder\u00e4ng U, Zaozerska N, Bachus E, Lindholm D, Petersson M, Langkilde AM. DELIVER Trial Committees and Investigators. 2022. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. <i>N Engl J Med<\/i> 387: 1089\u20131098.","DOI":"10.1056\/NEJMoa2206286"},{"key":"129","doi-asserted-by":"crossref","unstructured":"129. Sridhar VS, Tuttle KR, Cherney DZI.  2020. We can finally stop worrying about SGLT2 inhibitors and acute kidney injury. <i>Am J Kidney Dis<\/i> 76: 454\u2013456.","DOI":"10.1053\/j.ajkd.2020.05.014"},{"key":"130","unstructured":"130. Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Petrini M, Massey D, Eilbracht J, Brueckmann M, Landray MJ, Baigent C, Haynes R. The EMPA-KIDNEY Collaborative Group. 2023. Empagliflozin in patients with chronic kidney disease. <i>N Engl J Med<\/i> 388: 117\u2013127."},{"key":"131","doi-asserted-by":"crossref","unstructured":"131. Trull\u00e0s JC, Casado J, Morales-Rull JL, Formiga F, Conde-Martel A, Quir\u00f3s R, Epelde F, Gonz\u00e1lez-Franco \u00c1, Manzano L, Montero-P\u00e9rez-Barquero M.  2019. Prevalence and outcome of diuretic resistance in heart failure. <i>Intern Emerg Med<\/i> 14: 529\u2013537.","DOI":"10.1007\/s11739-018-02019-7"},{"key":"132","doi-asserted-by":"crossref","unstructured":"132. Tsutsui H, Isobe M, Ito H, Ito H, Okumura K, Ono M, Kitakaze M, Kinugawa K, Kihara Y, Goto Y, Komuro I, Saiki Y, Saito Y, Sakata Y, Sato N, Sawa Y, Shiose A, Shimizu W, Shimokawa H, Seino Y, Node K, Higo T, Hirayama A, Makaya M, Masuyama T, Murohara T, Momomura SI, Yano M, Yamazaki K, Yamamoto K, Yoshikawa T, Yoshimura M, Akiyama M, Anzai T, Ishihara S, Inomata T, Imamura T, Iwasaki YK, Ohtani T, Onishi K, Kasai T, Kato M, Kawai M, Kinugasa Y, Kinugawa S, Kuratani T, Kobayashi S, Sakata Y, Tanaka A, Toda K, Noda T, Nochioka K, Hatano M, Hidaka T, Fujino T, Makita S, Yamaguchi O, Ikeda U, Kimura T, Kohsaka S, Kosuge M, Yamagishi M, Yamashina A. Japanese Circulation Society and the Japanese Heart Failure Society Joint Working Group. 2019. JCS 2017\/JHFS 2017 guideline on diagnosis and treatment of acute and chronic heart failure \u2212digest version. <i>Circ J<\/i> 83: 2084\u20132184.","DOI":"10.1253\/circj.CJ-19-0342"},{"key":"133","unstructured":"133. U.S. Food &amp; Drug Administration. Food and Drug Administration [Clinical Pharmacology &amp; Biopharmaceutics Review (part 1)] for original New Drug Application 022081. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2007\/022081s000TOC.cfm [accessed on January 29, 2025]."},{"key":"134","unstructured":"134. U.S. Food &amp; Drug Administration. Drugs@FDA: FDA-Approved Drugs. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm [accessed on January 29, 2025]."},{"key":"135","doi-asserted-by":"crossref","unstructured":"135. Uechi M, Shimizu A, Mizuno M.  2002. Heart rate modulation by sympathetic nerves in dogs with heart failure. <i>J Vet Med Sci<\/i> 64: 1023\u20131029.","DOI":"10.1292\/jvms.64.1023"},{"key":"136","doi-asserted-by":"crossref","unstructured":"136. Upadhyay A.  2024. SGLT2 inhibitors and kidney protection: Mechanisms beyond tubuloglomerular feedback. <i>Kidney360<\/i> 5: 771\u2013782.","DOI":"10.34067\/KID.0000000000000425"},{"key":"137","doi-asserted-by":"crossref","unstructured":"137. Uthman L, Baartscheer A, Bleijlevens B, Schumacher CA, Fiolet JWT, Koeman A, Jancev M, Hollmann MW, Weber NC, Coronel R, Zuurbier CJ.  2018. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na<sup>+<\/sup>\/H<sup>+<\/sup> exchanger, lowering of cytosolic Na<sup>+<\/sup> and vasodilation. <i>Diabetologia<\/i> 61: 722\u2013726.","DOI":"10.1007\/s00125-017-4509-7"},{"key":"138","doi-asserted-by":"crossref","unstructured":"138. van Deursen VM, Urso R, Laroche C, Damman K, Dahlstr\u00f6m U, Tavazzi L, Maggioni AP, Voors AA.  2014. Co-morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey. <i>Eur J Heart Fail<\/i> 16: 103\u2013111.","DOI":"10.1002\/ejhf.30"},{"key":"139","doi-asserted-by":"crossref","unstructured":"139. Vander AJ, Carlson J.  1969. Mechanism of the effects of furosemide on renin secretion in anesthetized dogs. <i>Circ Res<\/i> 25: 145\u2013152.","DOI":"10.1161\/01.RES.25.2.145"},{"key":"140","doi-asserted-by":"crossref","unstructured":"140. Wess G, Kresken JG, Wendt R, Gaugele J, Killich M, Keller L, Simak J, Holler P, Bauer A, K\u00fcchenhof H, Glaus T.  2020. Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial. <i>J Vet Intern Med<\/i> 34: 2232\u20132241.","DOI":"10.1111\/jvim.15863"},{"key":"141","doi-asserted-by":"crossref","unstructured":"141. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS. DECLARE\u2013TIMI 58 Investigators. 2019. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. <i>N Engl J Med<\/i> 380: 347\u2013357.","DOI":"10.1056\/NEJMoa1812389"},{"key":"142","doi-asserted-by":"crossref","unstructured":"142. Wright EM, Loo DDF, Hirayama BA.  2011. Biology of human sodium glucose transporters. <i>Physiol Rev<\/i> 91: 733\u2013794.","DOI":"10.1152\/physrev.00055.2009"},{"key":"143","doi-asserted-by":"crossref","unstructured":"143. Writing Committee MembersACC\/AHA Joint Committee Members. 2022. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure. <i>J Card Fail<\/i> 28: e1\u2013e167.","DOI":"10.1016\/j.cardfail.2022.03.346"},{"key":"144","doi-asserted-by":"crossref","unstructured":"144. Yau K, Dharia A, Alrowiyti I, Cherney DZI.  2022. Prescribing SGLT2 inhibitors in patients with CKD: Expanding indications and practical considerations. <i>Kidney Int Rep<\/i> 7: 1463\u20131476.","DOI":"10.1016\/j.ekir.2022.04.094"},{"key":"145","doi-asserted-by":"crossref","unstructured":"145. Yeary RA.  1975. Systemic toxic effects of chemotherapeutic agents in domestic animals. <i>Vet Clin North Am<\/i> 5: 51\u201369.","DOI":"10.1016\/S0091-0279(75)50003-1"},{"key":"146","doi-asserted-by":"crossref","unstructured":"146. Yerra VG, Connelly KA.  2024. Extrarenal benefits of SGLT2 inhibitors in the treatment of cardiomyopathies. <i>Physiology (Bethesda)<\/i> 39: 0.","DOI":"10.1152\/physiol.00008.2024"},{"key":"147","doi-asserted-by":"crossref","unstructured":"147. Yuan X, Pan L, Zhang C, Zhu Q, Huang Z, Qin Y, Zhang G, Feng Z, Yang C, Hou N.  2024. Empagliflozin improves pressure-overload-induced cardiac hypertrophy by inhibiting the canonical Wnt\/\u03b2-catenin signaling pathway. <i>Front Pharmacol<\/i> 15: 1499542.","DOI":"10.3389\/fphar.2024.1499542"},{"key":"148","doi-asserted-by":"crossref","unstructured":"148. Yurista SR, Sillj\u00e9 HHW, Oberdorf-Maass SU, Schouten EM, Pavez Giani MG, Hillebrands JL, van Goor H, van Veldhuisen DJ, de Boer RA, Westenbrink BD.  2019. Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction. <i>Eur J Heart Fail<\/i> 21: 862\u2013873.","DOI":"10.1002\/ejhf.1473"},{"key":"149","doi-asserted-by":"crossref","unstructured":"149. Zelniker TA, Braunwald E.  2020. Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review. <i>J Am Coll Cardiol<\/i> 75: 422\u2013434.","DOI":"10.1016\/j.jacc.2019.11.031"},{"key":"150","doi-asserted-by":"crossref","unstructured":"150. Zhang X, Wang N, Fu P, An Y, Sun F, Wang C, Han X, Zhang Y, Yu X, Liu Y.  2023. Dapagliflozin attenuates heart failure with preserved ejection fraction remodeling and dysfunction by elevating \u03b2-hydroxybutyrate-activated citrate synthase. <i>J Cardiovasc Pharmacol<\/i> 82: 375\u2013388.","DOI":"10.1097\/FJC.0000000000001474"},{"key":"151","doi-asserted-by":"crossref","unstructured":"151. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE. EMPA-REG OUTCOME Investigators. 2015. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. <i>N Engl J Med<\/i> 373: 2117\u20132128.","DOI":"10.1056\/NEJMoa1504720"}],"container-title":["Journal of Veterinary Medical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jvms\/87\/6\/87_25-0040\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T04:40:20Z","timestamp":1749271220000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jvms\/87\/6\/87_25-0040\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":151,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1292\/jvms.25-0040","relation":{},"ISSN":["0916-7250","1347-7439"],"issn-type":[{"value":"0916-7250","type":"print"},{"value":"1347-7439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"25-0040"}}